Please see my new article on LinkedIn.
Please see my new article on LinkedIn.
As mentioned in my previous post, I am back to business school. Since this is full-time, intensive 5 months and 6 days/week program, I may be unable to post before May. I promise the break is just temporary and I will be back with more articles this year.
Per update to the below post: Yoga, Neophobic Parrot, and Exciting News: the manuscript I wrote for the Clinical Pharmacology & Therapeutics journal was just accepted. It will be published in a special Jul 2018 issue focusing on the topic of intelligent design digital devices. It is intended for a clinical audience and discusses the impact of the smart devices on the productivity of drug development.🍾🥂🎆
The pharmaceutical R&D portfolio is usually formed by combining several assets. It can include discovery, pre-clinical and development stage small molecules and biologics (Phase I-IV) or medical devices. Less mature biotech companies, usually own either single project or platform and there is not yet a real R&D portfolio to manage. Large pharma or biotech organizations have actual and sometimes complex portfolios with numerous projects at various stages of development. Decisions around portfolio such as selection of the drug candidates, portfolio prioritization, and optimization are the most critical areas driving a total shareholder value for the organization. The portfolio management is a dynamic process and methodologies used vary among companies. The size of the company and portfolio dictates the complexity and work intensity of the portfolio management. Relevant decisions are made according to a predetermined process and by evaluating multiple parameters. Some of the portfolio management components may be outsourced if there is a need for it. Final accountability for the portfolio decisions stays with the R&D executive team and board of directors. Continue reading
Hello All, I do not do this usually, but I want to bring your attention to a great article by John Todd, Project Management Insitute. I had a pleasure to work with John, who is very thorough PMI researcher, as one of the respondents. I shared some of my pharma R&D project management experiences that served as a base for the article below.
If you are in a company which would like to participate in the above program/interviews, please let me know and I will connect you with John!
Recently, I have been supporting a good friend who suffers from various health issues. During the process, we discovered that alternative therapies, not hard medicines, are often beneficial. Exercise, acupuncture, acupressure, meditation, herbal or dietary supplements often may come to rescue as prescribed medication alone may not resolve the health issues. In combination, however, they can reach the desired effect (cure or improvement of the condition). Continue reading
Finance is a broad term describing the management of money and other valuables, which can be easily converted into cash to achieve economic objectives of the given organization. The usual structure of the financial department in large, mature pharmaceutical company includes Tax Group (scope: tax declarations & optimization, transfer pricing), Accounting (scope: external reporting, financial data management), Corporate Finance (scope: treasury & capital markets, M&A, investor relations), Controlling (scope: internal reporting, budgeting & planning, business valuation), plus potentially additional groups. Continue reading
Biotechnological and Pharmaceutical companies are usually very different entities. Biotech exists primarily for the innovation and discovery. Pharma companies mainly aim to develop, commercialize and sell their own or acquired products. Therefore, those two types of companies usually take on a very different business model. Continue reading
The United States (US) has a population of over 324 million people and one of the most complex healthcare systems in the world. US health care system is in a constant state of change. The United States spends the most on health care per person — $9,237 – according to two new papers published in the journal The Lancet ($3.2 trillion total in 2015). For comparison, the global spending on health in 2014 was US$9·21 trillion. Continue reading